CN Patent
CN101347431A — 弗利班西林在治疗性障碍中的用途
Assigned to Boehringer Ingelheim Pharma GmbH and Co KG · Expires 2009-01-21 · 17y expired
What this patent protects
本发明是关于弗利班西林(FLIBANSERIN)在制备用于治疗性需求疾病的药物中的用途。
USPTO Abstract
本发明是关于弗利班西林(FLIBANSERIN)在制备用于治疗性需求疾病的药物中的用途。
Drugs covered by this patent
- Addyi (FLIBANSERIN) · Sprout Pharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.